Our partnering activities are centered around the company’s pipeline of theranostic radiopharmaceutical drug candidates. Over the past few years, 3BP has created a diversified early stage product pipeline. Three programs have already been out-licensed at the discovery, preclinical and early clinical stage and those are now being funded and driven forward by dedicated players in the pharmaceutical industry.

Current and future partnering goals:

  • Enter into additional collaborative discovery alliances for molecular targeted radiopharmaceuticals
  • In-license complementary nuclear medicine assets across all development stages
  • Out-license proprietary pipeline programs

3BP`s business development team will be happy to discuss your projects and licensing opportunities at one of the upcoming biopharma trade-shows and to review incoming proposals. Please submit non-confidential materials via email to the dedicated inbox listed on our contact page.